哌罗匹隆与利培酮治疗首发精神分裂症对照研究

A control study of perospi rone vs .risperidone in the treatment of first-episode schizophrenia

目的：探讨哌罗匹隆与利培酮治疗首发精神分裂症患者的临床疗效和安全性。方法将120例首发精神分裂症患者随机分为两组，研究组口服哌罗匹隆治疗，对照组口服利培酮治疗，观察8周。采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果治疗后两组阳性与阴性症状量表总分及各因子分均较治疗前显著下降（ P＜0．05或0．01），治疗8周末研究组总有效率为83．3％，对照组为81．7％，两组比较差异无显著性（χ^2＝0．06，P＞0．05）。研究组不良反应发生率为56．7％，对照组为53．3％，两组比较差异无显著性（χ^2＝0．13，P＞0．05），但研究组体质量增加、月经改变及泌乳、性欲改变等不良反应发生率低于对照组。结论哌罗匹隆与利培酮治疗首发精神分裂症疗效显著，安全性高，依从性好，但哌罗匹隆较少引起内分泌改变和体质量增加，更适用于女性首发精神分裂症患者。

Objective To explore the efficacy and safety of perospirone and risperidone in the treatment of first‐episode schizophrenia .Methods A total of 120 first‐episode schizophrenics were randomly divided into two groups ,research group took orally perospirone and control group did risperidone for 8 weeks .Ef‐ficacies were assessed with the Positive and Negative Syndrome Scale （PANSS） and adverse reactions with the Treatment Emergent Symptom Scale （TESS） .Results After treatment the total and each factor scores of the PANSS of both groups lowered more significantly compared with pretreatment （P〈0 .05 or 0 .01） ,at the end of the 8th week total effective rate was respectively 83 .3% in research and 81 .7% in con‐trol group ,which showed no significant difference （χ^2 =0 .06 ,P〉0 .05） .The incidence of adverse reaction was respectively 56 .7% in research and 53 .3% in control group ,which showed no significant difference （χ^2 = 0 .13 ,P〉 0 .05） ,but the incidences of weight gain ,menstruation change ,lactation and sexuality change were significantly lower in research than in control group .Conclusion Both perospirone and ris‐peridone have an evident effect ,higher safety and better safety in the treatment of first‐episode schizophre‐nia ,but the former causes less endocrine alteration and weight gain and is more suitable to female first‐epi‐sode schizophrenic .